Security key
M96088105
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)
CUSIP: M96088105
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Ordinary Shares, par value NIS 0.01 per share
- Shares outstanding
- 48,684,257
- Total 13F shares
- 43,711,574
- Share change
- -54,776
- Total reported value
- $1,023,591,933
- Put/Call ratio
- 15%
- Price per share
- $23.42
- Number of holders
- 167
- Value change
- +$14,662,063
- Number of buys
- 81
- Number of sells
- 75
Report period
Q4 2025
Institutions
167
Top holders
10
URGN full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
UroGen Pharma Ltd. SEC filings
UroGen Pharma Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M96088105
Recent filing periods:
Top shareholders of URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| MORGAN STANLEY |
13F
13D/G
|
Company |
5.4%
from 13D/G
|
2,528,446
|
$50,442,497 | — | 30 Sep 2025 | |
| MENORA MIVTACHIM HOLDINGS LTD. |
13D/G
13F
|
Company |
5%
|
2,303,031
|
$24,780,614 | $0 | 11 Mar 2025 | |
| Soleus Capital Master Fund, L.P. |
13D/G
|
— |
4.7%
|
2,185,000
|
$31,114,400 | -$1,993,600 | 30 Jun 2025 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
2.8%
|
1,277,000
|
$13,740,520 | -$17,765,685 | 31 Mar 2025 | |
| Monograph Capital Holdings Advisors, LLC |
13D/G
|
Monograph Capital Partners I, L.P. |
1.8%
|
838,615
|
$8,503,556 | $0 | 05 Jun 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
9.3%
|
4,543,895
|
$90,650,705 | — | 30 Sep 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
8.7%
|
4,216,084
|
$84,110,876 | — | 30 Sep 2025 | |
| TORONTO DOMINION BANK |
13F
|
Company |
6.6%
|
3,190,510
|
$63,650,675 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
5.3%
|
2,581,286
|
$51,496,656 | — | 30 Sep 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
4.5%
|
2,199,652
|
$43,883,057 | — | 30 Sep 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.2%
|
1,577,283
|
$31,466,796 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
3%
|
1,468,737
|
$29,301,303 | — | 30 Sep 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
2.6%
|
1,259,749
|
$25,131,993 | — | 30 Sep 2025 | |
| SG Americas Securities, LLC |
13F
|
Company |
2.4%
|
1,157,383
|
$23,090,000 | — | 30 Sep 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.1%
|
1,000,000
|
$19,950,000 | — | 30 Sep 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.8%
|
888,933
|
$17,734,213 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.7%
|
819,446
|
$16,347,948 | — | 30 Sep 2025 | |
| Migdal Insurance & Financial Holdings Ltd. |
13F
|
Company |
1.6%
|
770,909
|
$15,380,000 | — | 30 Sep 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.5%
|
717,347
|
$14,311,073 | — | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.4%
|
689,000
|
$13,745,550 | — | 30 Sep 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
687,475
|
$13,715,126 | — | 30 Sep 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
1.4%
|
679,000
|
$13,546,050 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.2%
|
602,277
|
$12,015,426 | — | 30 Sep 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1.2%
|
575,000
|
$11,471,250 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.1%
|
534,545
|
$10,664,172 | — | 30 Sep 2025 | |
| Nuveen, LLC |
13F
|
Company |
1%
|
507,531
|
$10,125,244 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.97%
|
471,229
|
$9,401,017 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.87%
|
424,916
|
$8,477,074 | — | 30 Sep 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.83%
|
402,595
|
$8,031,770 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.79%
|
386,203
|
$7,704,750 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.73%
|
356,615
|
$7,116,000 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.67%
|
328,419
|
$6,551,959 | — | 30 Sep 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.63%
|
308,328
|
$6,151,144 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.63%
|
306,371
|
$6,112,101 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.62%
|
303,785
|
$6,060,511 | — | 30 Sep 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.61%
|
297,851
|
$5,942,125 | — | 30 Sep 2025 | |
| Atom Investors LP |
13F
|
Company |
0.6%
|
291,962
|
$5,824,642 | — | 30 Sep 2025 | |
| Kynam Capital Management, LP |
13F
|
Company |
0.58%
|
282,412
|
$6,935,707 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.57%
|
275,100
|
$5,488,245 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.54%
|
261,401
|
$5,214,951 | — | 30 Sep 2025 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.53%
|
259,143
|
$5,169,893 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.42%
|
204,191
|
$4,073,611 | — | 30 Sep 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.4%
|
196,622
|
$3,922,609 | — | 30 Sep 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.39%
|
190,452
|
$3,799,517 | — | 30 Sep 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.38%
|
184,382
|
$3,678,421 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.37%
|
180,460
|
$3,600,176 | — | 30 Sep 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.33%
|
162,259
|
$3,237,068 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.3%
|
147,225
|
$2,937,139 | — | 30 Sep 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
0.28%
|
135,000
|
$2,693,250 | — | 30 Sep 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.27%
|
133,674
|
$2,666,000 | — | 30 Sep 2025 |
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q4 2025
As of 31 Dec 2025,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
167 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
43,711,574 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, BlackRock, Inc., MORGAN STANLEY, Jefferies Financial Group Inc., SILVERARC CAPITAL MANAGEMENT, LLC, ACORN CAPITAL ADVISORS, LLC, SG Americas Securities, LLC, AMERICAN CENTURY COMPANIES INC, and MENORA MIVTACHIM HOLDINGS LTD..
This page lists
167
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
159
Q4 2025 holders
167
Holder diff
8
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.